Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
FOXO Technologies Inc. (FOXO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/03/2025: FOXO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -79.36% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.91M USD | Price to earnings Ratio 2.46 | 1Y Target Price - |
Price to earnings Ratio 2.46 | 1Y Target Price - | ||
Volume (30-day avg) 9462191 | Beta 3.52 | 52 Weeks Range 0.11 - 1.30 | Updated Date 04/1/2025 |
52 Weeks Range 0.11 - 1.30 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.05 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -84.03% |
Management Effectiveness
Return on Assets (TTM) -20.35% | Return on Equity (TTM) -1754.5% |
Valuation
Trailing PE 2.46 | Forward PE - | Enterprise Value 38540450 | Price to Sales(TTM) 2.17 |
Enterprise Value 38540450 | Price to Sales(TTM) 2.17 | ||
Enterprise Value to Revenue 28.74 | Enterprise Value to EBITDA -0.33 | Shares Outstanding 23572800 | Shares Floating 15960132 |
Shares Outstanding 23572800 | Shares Floating 15960132 | ||
Percent Insiders 9.9 | Percent Institutions 2.69 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
FOXO Technologies Inc.
Company Overview
History and Background
FOXO Technologies Inc. was founded in 2021 and went public in March 2023. The company focuses on longevity science, data analytics, and developing epigenetic biomarkers for life insurance and other applications.
Core Business Areas
- Life Insurance: Develops and licenses epigenetic technology to life insurance companies to improve risk assessment and underwriting.
- Longevity Research: Conducts research and development related to longevity science and epigenetic biomarkers.
- Data Analytics: Offers data analytics services related to longevity and epigenetic data.
Leadership and Structure
The leadership team includes Jon Sabes (CEO) and Dr. Brian Chen (Chief Science Officer). The company has a board of directors overseeing its operations.
Top Products and Market Share
Key Offerings
- FOXO EpiAge Test: Epigenetic test used to predict biological age. They partner with life insurance companies to help with policy underwriting. There is no current market share to report. Competitors include companies offering biological age tests like Elysium Health (Basis) and Tally Health.
- FOXO LIFE Platform: Data platform for life insurance companies to use epigenetic data for risk assessment and policy pricing. There is no current market share to report, the platform is focused towards Life Insurance companies. Competitors include traditional actuarial science and underwriting tools from companies like RGA and Munich Re.
Market Dynamics
Industry Overview
The longevity market is rapidly growing, driven by increasing interest in personalized medicine, preventative healthcare, and advancements in epigenetic research. The life insurance industry is also increasingly exploring new risk assessment methods.
Positioning
FOXO Technologies Inc. is positioning itself as a leader in epigenetic-based risk assessment for the life insurance industry. Its competitive advantage lies in its proprietary epigenetic technology and data analytics capabilities.
Total Addressable Market (TAM)
The total addressable market for longevity and personalized medicine is estimated to be in the hundreds of billions of dollars. FOXO Technologies Inc. is positioned to capture a share of this market by partnering with life insurance companies and developing innovative epigenetic-based products.
Upturn SWOT Analysis
Strengths
- Proprietary epigenetic technology
- Expertise in longevity science
- Partnerships with life insurance companies
- Focus on data analytics
Weaknesses
- Limited operating history
- Relatively small market capitalization
- Dependence on life insurance industry adoption
- Not currently profitable
Opportunities
- Expanding partnerships with life insurance companies
- Developing new epigenetic-based products
- Entering new markets such as healthcare and wellness
- Growing demand for personalized medicine
Threats
- Competition from established life insurance companies
- Regulatory changes affecting epigenetic testing
- Economic downturn impacting the life insurance industry
- Scientific breakthroughs rendering epigenetic testing obsolete
Competitors and Market Share
Key Competitors
- Elysium Health (Private)
- Tally Health (Private)
- RGA (RGA)
- Munich Re (MUV2.DE)
Competitive Landscape
FOXO Technologies Inc. faces competition from established life insurance companies and other longevity companies. Its advantage is its focus on epigenetic technology, but it needs to demonstrate the value of its products to gain market share.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's short operating history.
Future Projections: Future projections are based on analyst estimates, which are subject to change. Analysts expect the company to grow through its partnerships with life insurance companies and the development of new epigenetic-based products. Projections are highly speculative given the company's limited operating history and dependence on market acceptance.
Recent Initiatives: Recent initiatives include securing new partnerships with life insurance companies and launching new epigenetic testing services.
Summary
FOXO Technologies Inc. is a relatively new company in the longevity and life insurance space, with a focus on epigenetic technology. Its strength lies in its proprietary technology and partnerships with life insurance companies. The company's weaknesses include its limited operating history and dependence on market adoption. Investors should consider the company's financial performance and competitive landscape before investing.
Similar Companies
- RGA
- MUV2.DE
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Investment decisions should be made based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About FOXO Technologies Inc.
Exchange NYSE MKT | Headquaters Minneapolis, MN, United States | ||
IPO Launch date 2021-01-29 | CEO & Director Mr. Seamus Lagan | ||
Sector Healthcare | Industry Health Information Services | Full time employees - | Website https://foxotechnologies.com |
Full time employees - | Website https://foxotechnologies.com | ||
FOXO Technologies Inc. develops epigenetic biomarkers technology solutions in the United States. The company applies automated machine learning and artificial intelligence (AI) technologies to discover epigenetic biomarkers of human health, wellness, and aging. It offers FOXO Labs, a commercializing proprietary epigenetic biomarker technology enables the adoption of saliva-based health and wellness biomarker solutions for underwriting and risk assessment; and Bioinformatics services that provides data solutions using AI and machine learning for data analysis and processing, and quality checking for academia, healthcare, government, and pharmaceutical research customers. FOXO Technologies Inc. was founded in 2020 and is based in Minneapolis, Minnesota.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.